Glutamic Acid

Glutamic Acid

SCHEMBL5823746

N[C@@H](CCC(=O)O)C(=O)O.O=C(O)C(=O)O

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Glutamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 0.90
GRM6 O15303 2/20 0.90
GRM7 Q14831 2/20 0.90
GRM4 Q14833 2/20 0.90
GSR P00390 2/20 0.90
GRIN2D O15399 1/20 0.90
GRIN3B O60391 1/20 0.90
CYP1A2 P05177 1/20 0.90
GRIK1 P39086 1/20 0.90
GRM5 P41594 1/20 0.90
GRIA1 P42261 1/20 0.90
GRIA2 P42262 1/20 0.90
GRIA3 P42263 1/20 0.90
SLC1A3 P43003 1/20 0.90
SLC1A2 P43004 1/20 0.90
SLC1A1 P43005 1/20 0.90
GRIA4 P48058 1/20 0.90
GRIN1 Q05586 1/20 0.90
GRIN2A Q12879 1/20 0.90
GRIK2 Q13002 1/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL5823743 1.00 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL28236392 0.95 GRM8 (0.82) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL410241 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL17127348 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL1554237 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL5704264 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL1330824 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL1330484 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL248800 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL2201 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180153931-A1 ANTITUMORAL COMBINATION COMPRISING CABAZITAXEL AND CISPLATIN AVENTIS PHARMA S.A. (FR) 2018-06-07 US disclosed
US-20140056996-A1 ANTITUMORAL COMBINATION COMPRISING CABAZITAXEL AND CISPLATIN AVENTIS PHARMA S.A. (FR) 2014-02-27 US disclosed
WO-2006082341-A1 CRYSTALLIZATION METHOD AND DEVICE CRYSTAL-EVAP CONSULT (FR) 2006-08-10 WO disclosed
EP-1319180-A2 MICRO-INVASIVE METHOD FOR PAINLESS DETECTION OF ANALYTES IN EXTRACELLULAR SPACE Becton, Dickinson and Company (US) 2003-06-18 EP disclosed
WO-2002025275-A2 MICRO-INVASIVE METHOD FOR PAINLESS DETECTION OF ANALYTES IN EXTRACELLULAR SPACE MICROSENSE INTERNATIONAL LLC (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180153931-A1 ANTITUMORAL COMBINATION COMPRISING CABAZITAXEL AND CISPLATIN GALC, GMNN, TYMP GRM8 4072/4885GRM6 3578/4885GRM7 2304/4885
US-20140056996-A1 ANTITUMORAL COMBINATION COMPRISING CABAZITAXEL AND CISPLATIN GALC, GMNN, TYMP GRM8 4072/4885GRM6 3578/4885GRM7 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.